Search

Your search keyword '"A Klein"' showing total 3,262 results

Search Constraints

Start Over You searched for: Author "A Klein" Remove constraint Author: "A Klein" Journal blood Remove constraint Journal: blood
3,262 results on '"A Klein"'

Search Results

1. Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)

2. Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange

3. Gasdermin D drives focal crystalline thrombotic microangiopathy by accelerating immunothrombosis and necroinflammation

4. Wiskott-Aldrich syndrome: a study of 577 patients defines the genotype as a biomarker for disease severity and survival

5. A lineage-specific STAT5BN642H mouse model to study NK-cell leukemia

6. CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy

7. Clinical and functional spectrum of RAC2-related immunodeficiency

8. Tumor necrosis factor α promotes clonal dominance of KIT D816V+ cells in mastocytosis: role of survivin and impact on prognosis

9. Disruption of cotranscriptional splicing suggests RBM39 is a therapeutic target in acute lymphoblastic leukemia

10. Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms

11. Human genetic defects in SRP19 and SRPRA cause severe congenital neutropenia with distinctive proteome changes

12. Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)

13. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis

14. Metabolomic identification of α-ketoglutaric acid elevation in pediatric chronic graft-versus-host disease

17. CD4+ T-cell reconstitution predicts survival outcomes after acute graft-versus-host-disease: a dual-center validation

18. Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange

19. Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers

21. Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial

23. Graft-Versus-Host Disease (GvHD) and Steroid-Refractory GvHD after Allogeneic Hematopoietic Stem Cell Transplantation: A Large Real-World EBMT-Based Epidemiology and Treatment Pattern Study

24. Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease : Results from Early Access Program in Europe

25. LMO2 activation by deacetylation is indispensable for hematopoiesis and T-ALL leukemogenesis

26. The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy

28. Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia.

29. Pelabresib (CPI-0610) Combined with Ruxolitinib for JAK Inhibitor Treatment-Naïve Patients with Myelofibrosis: Durability of Response and Safety Beyond Week 24

30. Pelabresib (CPI-0610) As Add-on to Ruxolitinib in Myelofibrosis: Durability of Response and Safety Beyond Week 24 in the Phase 2 MANIFEST Study

31. Tumor necrosis factor α promotes clonal dominance of KITD816V+cells in mastocytosis: role of survivin and impact on prognosis

33. Matching for the MICA-129 polymorphism is beneficial in unrelated hematopoietic stem cell transplantation

34. Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma

35. CD84: A Novel Target for CAR T-Cell Therapy for Acute Myeloid Leukemia

36. Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment: A Propensity Score Matching Analysis

37. Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure

38. Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma

40. Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma

42. Fatal autoimmunity in mice reconstituted with human hematopoietic stem cells encoding defective FOXP3

45. Metabolomic identification of α-ketoglutaric acid elevation in pediatric chronic graft-versus-host disease

46. Pelabresib (CPI-0610) As Add-on to Ruxolitinib in Myelofibrosis: Durability of Response and Safety Beyond Week 24 in the Phase 2 MANIFEST Study

47. Alterations of Immune Cells By Large B Cell Lymphoma Persist Years after Achieving Complete Remission and Correlate with Impaired Adaptive Immunity

49. In Patients with Relapsed/Refractory AML Sequential Conditioning and Immediate Allogeneic Stem Cell Transplantation (allo-HCT) Results in Similar Overall and Leukemia-Free Survival Compared to Intensive Remission Induction Chemotherapy Followed By Allo-HCT: Results from the Randomized Phase III ASAP Trial

50. Pelabresib (CPI-0610) Combined with Ruxolitinib for JAK Inhibitor Treatment-Naïve Patients with Myelofibrosis: Durability of Response and Safety Beyond Week 24

Catalog

Books, media, physical & digital resources